Views & Analysis | Perspectives on pharma industry issues

R&D

Inspection readiness is now a commercial question

Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

Articles

Achieving launch excellence in oncology: adapting to new mar...

As the oncology market is becoming increasingly harder to successfully enter, Dr. Simone Seiter and Maneesh Gupta highlight here the new “rules of the game” in achieving oncology launch excellence. Biotechnology and pharmaceutical companies are paying a high price as the oncology market matures and access is increasingly...

Articles

Genetic advances towards personalised medicine: hope for rar...

In our latest interview Rebecca Aris talks to Pierrick Rollet, a well known figure in UK pharma, to hear his advice for the next generation of industry leaders. The field of genetics is advancing dramatically and with these advances the prospect of personalised medicine become increasingly more...

Articles

Women with history of breast cancer have lower quality of li...

As breast cancer incidence increases, it’s important we understand the long-term impact of the disease on the patient. Marco DiBonaventura and Ian Dunham look into an overlooked area – quality of life in those with a history of breast cancer. Breast cancer is the most common form of cancer among women in Western Europe, it has the greatest cancer mortality in women and...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.